Reached Settlement for Hikma Pharmaceuticals in Hatch-Waxman Litigation
June 14, 2022
Astellas US LLC v. Hikma Pharmaceuticals USA, Inc., 21-1785-CFC (D. Del.)
Robins Kaplan LLP reached a settlement on behalf of generic pharmaceutical manufacturer Hikma Pharmaceuticals USA, Inc., in a patent litigation arising from the Hatch-Waxman Act. Plaintiffs, who make and sell Lexiscan® (regadenoson), asserted claims for patent infringement of three patents-in-suit against Defendant, after having filed its Abbreviated New Drug Application with the FDA, seeking to make and market a generic version of regadenoson. Defendant alleged that the patents-in-suit were invalid and/or not infringed. The case settled on confidential terms.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.